Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to 0.72.

  • Niagen Bioscience's Equity Ratio rose 1843.52% to 0.72 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.72, marking a year-over-year increase of 1843.52%. This contributed to the annual value of 0.68 for FY2024, which is 3039.71% up from last year.
  • Niagen Bioscience's Equity Ratio amounted to 0.72 in Q3 2025, which was up 1843.52% from 0.7 recorded in Q2 2025.
  • Niagen Bioscience's Equity Ratio's 5-year high stood at 0.72 during Q3 2025, with a 5-year trough of 0.45 in Q2 2022.
  • Over the past 5 years, Niagen Bioscience's median Equity Ratio value was 0.54 (recorded in 2021), while the average stood at 0.57.
  • In the last 5 years, Niagen Bioscience's Equity Ratio tumbled by 3035.59% in 2022 and then surged by 3039.71% in 2024.
  • Quarter analysis of 5 years shows Niagen Bioscience's Equity Ratio stood at 0.55 in 2021, then dropped by 3.3% to 0.53 in 2022, then dropped by 2.39% to 0.52 in 2023, then surged by 30.4% to 0.68 in 2024, then increased by 6.68% to 0.72 in 2025.
  • Its last three reported values are 0.72 in Q3 2025, 0.7 for Q2 2025, and 0.68 during Q1 2025.